Christopher Lord

Christopher Lord at the Institute of Cancer Research co-discovered PARP inhibitor synthetic lethality with BRCA2 alongside Alan Ashworth and is a world expert in synthetic lethality screening. His laboratory uses CRISPR and RNAi screens to systematically identify novel synthetic lethal interactions with oncogenic mutations including BRCA, KRAS, and chromatin-remodeling gene defects. His work has extended synthetic lethality beyond PARP/BRCA to new drug targets including WRN helicase, CDK12, and others. He develops the conceptual and experimental frameworks that guide the next generation of synthetic lethality-based cancer therapies.